Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor

被引:73
|
作者
Creamer, D
Allen, M
Jaggar, R
Stevens, R
Bicknell, R
Barker, J
机构
[1] Kings Coll Hosp London, St Johns Inst Dermatol, St Thomas Hosp, London SE5 9RS, England
[2] Imperial Canc Res Fund, Inst Mol Med, Mol Angiogenesis Grp, Oxford, England
[3] St Thomas Hosp, Dept Rheumatol, London, England
关键词
D O I
10.1001/archderm.138.6.791
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Severe forms of psoriasis can be complicated by systemic microvascular hyper-permeability. Vascular endothelial growth factor (VEGF) possesses potent vascular permeability activity. We suggest that VEGF enters the systemic circulation and acts on microvessels to mediate hyperpermeability. Objectives: To quantify renal microvascular permeability and circulating VEGF concentration in severe psoriasis, and to investigate the relationship between plasma VEGF concentration and skin and joint involvement. Design: Inception cohort studies of patients with generalized pustular psoriasis and plaque psoriasis. Setting: St John's Institute of Dermatology, London, England. Patients: Twenty-two patients (15 men and 7 women) with moderate and severe psoriasis were recruited (age range, 29-77 years; mean age, 47 years); 5 had generalized pustular psoriasis, 2 had erythrodermic psoriasis, and 15 had moderate-severe plaque psoriasis. An age- and sex-matched control group of 17 individuals (10 men and 7 women) was recruited (age range, 29-69 years; mean age, 42 years). Results: There was pathological proteinuria in patients with relapsing generalized pustular psoriasis, (4-fold increase in urinary protein excretion rate in relapse compared with remission). In patients with moderate and severe psoriasis, mean plasma VEGF concentration during relapse was approximately 2.5 times greater than during remission (mean VEGF(relapse)=257 pg/mL; mean VEGF(remission)=103 pg/mL; P<.01). There was a correlation between extent of skin involvement and plasma VEGF level (mean VEGF(severe) (psoriasis) = 365 pg/ml; mean VEGF(moderate psoriasis) = 149 pg/mL; P=.03). There was a correlation between presence of psoriatic arthritis and plasma VEGF level (mean relapse VEGF(arthritis)=277 pg/mL; mean relapse VEGF(nonarthritis),= 103.5 pg/mL; P=.03). Conclusions: Generalized pustular psoriasis is accompanied by pathological proteinuria and elevated plasma VEGF levels. Plasma VEGF concentration is significantly elevated in patients with extensive skin and joint involvement and may act on renal microvasculature to induce hyperpermeability.
引用
收藏
页码:791 / 796
页数:6
相关论文
共 50 条
  • [41] Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis
    Bhushan, M
    McLaughlin, B
    Weiss, JB
    Griffiths, CEM
    BRITISH JOURNAL OF DERMATOLOGY, 1999, 141 (06) : 1054 - 1060
  • [42] Systemic effects of intravitreal vascular endothelial growth factor inhibitors
    Campbell, Robert J.
    Bell, Chaim M.
    Campbell, Erica de L. P.
    Gill, Sudeep S.
    CURRENT OPINION IN OPHTHALMOLOGY, 2013, 24 (03) : 197 - 204
  • [43] VASCULAR ENDOTHELIAL GROWTH FACTOR IN TEARS OF SYSTEMIC SCLEROSIS PATIENTS
    Rentka, Aniko
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [44] Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis
    Weidemann, Anja K.
    Crawshaw, Ania A.
    Byrne, Emily
    Young, Helen S.
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2013, 6 : 233 - 244
  • [45] Genetic control of cellular production of vascular endothelial growth factor in psoriasis
    Young, HS
    Summers, AM
    Brenchley, PE
    Griffiths, CE
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 122 (03) : A3 - A3
  • [46] Vascular endothelial growth factor in psoriasis: an indicator of disease severity and control
    Nofal, A.
    Al-Makhzangy, I.
    Attwa, E.
    Nassar, A.
    Abdalmoati, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2009, 23 (07) : 803 - 806
  • [47] Retinoid pharmacogenetics and vascular endothelial growth factor in chronic plaque psoriasis
    Young, HS
    Summers, AM
    Read, I
    Fairhurst, D
    Plant, D
    Campalani, E
    Smith, CH
    Barker, JNWN
    Detmar, MJ
    Brenchley, PEC
    Griffiths, CEM
    BRITISH JOURNAL OF DERMATOLOGY, 2005, 153 : 9 - 10
  • [48] Evidence for vascular endothelial growth factor (VEGF) as a modifier gene in psoriasis
    Detmar, M
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 122 (01) : XIV - XV
  • [49] Vascular endothelial growth factor in severe sepsis and septic shock
    Karlsson, Sari
    Pettila, Ville
    Tenhunen, Jyrki
    Lund, Vesa
    Hovilehto, Seppo
    Ruokonen, Esko
    ANESTHESIA AND ANALGESIA, 2008, 106 (06): : 1820 - 1826
  • [50] Circulating level of vascular endothelial growth factor in differentiating hemangioma from vascular malformation patients
    Zhang, L
    Lin, XX
    Wang, W
    Zhuang, X
    Dong, FS
    Qi, ZL
    Flu, QH
    PLASTIC AND RECONSTRUCTIVE SURGERY, 2005, 116 (01) : 200 - 204